Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report

Taisuke Matsuoka; Takahisa Fujikawa; Yusuke Uemoto; Yuki Aibe; Suguru Hasegawa

doi:10.7759/cureus.45176

Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report

Cureus. 2023 Sep 13;15(9):e45176. doi: 10.7759/cureus.45176. eCollection 2023 Sep.

Authors

Taisuke Matsuoka¹, Takahisa Fujikawa¹, Yusuke Uemoto¹, Yuki Aibe², Suguru Hasegawa³

Affiliations

¹ Surgery, Kokura Memorial Hospital, Kitakyushu, JPN.
² Gastroenterology, Kokura Memorial Hospital, Kitakyushu, JPN.
³ Gastroenterological Surgery, Fukuoka University Hospital, Fukuoka, JPN.

Abstract

Hepatocellular carcinoma is a malignancy with an increasing incidence worldwide and is one of the most serious cancers in adults. We encountered a case of initially unresectable massive hepatocellular carcinoma in which conversion to curative resection and pathological complete response were achieved after atezolizumab plus bevacizumab therapy. Atezolizumab plus bevacizumab combination chemotherapy may be one of the most promising options for unresectable hepatocellular carcinoma.

Keywords: atezolizumab plus bevacizumab; conversion surgery; hepatocellular carcinoma; pathological complete response; robotic liver resection.

Publication types

Case Reports